Shenzhen Children's Hospital

Running trials

• Not yet recruiting

  Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A

  NCT06136507· Phase 3· Hangzhou Gensciences Biopharmaceutical Co., Ltd.· Source

• Recruiting

  The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature

  NCT07614152· Phase 3· Xiamen Amoytop Biotech Co., Ltd.· Source

• Recruiting

  Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)

  NCT07719140· Phase 4· Peking Union Medical College Hospital· Source

• Recruiting

  Fecal Microbiota Transplantation in Children With ASD

  NCT07381374· Shenzhen Children's Hospital· Source

• Recruiting

  A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

  NCT06807281· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

  NCT06807268· Phase 3· Pfizer· Source

• Recruiting

  Tracjectories and Predictors of Chemotherapy Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia

  NCT07326930· The Hong Kong Polytechnic University· Source

• Active, not recruiting

  Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III

  NCT06971094· Phase 3· GeneCradle Inc· Source

• Recruiting

  An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

  NCT05066217· Phase 3· Epygenix· Source

• Recruiting

  Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

  NCT07152041· Phase 3· Institute of Hematology & Blood Diseases Hospital, China· Source

• Recruiting

  Newly-diagnosed Pediatric T-cell ALL Protocol

  NCT06855810· Phase 2/3· Institute of Hematology & Blood Diseases Hospital, China· Source

• Enrolling by invitation

  A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

  NCT06908226· Phase 3· Longboard Pharmaceuticals· Source

• Recruiting

  Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

  NCT06764238· Phase 2/3· Institute of Hematology & Blood Diseases Hospital, China· Source

• Recruiting

  Long-term Follow-up Study of BRL-101 for TDT

  NCT06298630· Bioray Laboratories· Source

• Enrolling by invitation

  Risk Model for Metastasis Detection of Neuroblastoma

  NCT06703944· Xinhua Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Active, not recruiting

  A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

  NCT06719141· Phase 3· Longboard Pharmaceuticals· Source

• Active, not recruiting

  A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

  NCT06660394· Phase 3· Longboard Pharmaceuticals· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

  NCT06461897· Phase 3· AbbVie· Source

• Recruiting

  Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.

  NCT06655662· Phase 1· Shenzhen Hemogen· Source

• Recruiting

  A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

  NCT05319353· Phase 3· Takeda· Source

• Active, not recruiting

  Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

  NCT05577312· Phase 1/2· Bioray Laboratories· Source

• Recruiting

  Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry

  NCT06417502· Peking Union Medical College Hospital· Source

• Recruiting

  A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

  NCT05334823· Phase 2· Chongqing Precision Biotech Co., Ltd· Source

• Active, not recruiting

  Pediatric Spinal Muscular Atrophy (SMA) China Registry

  NCT05042921· Biogen· Source

• Active, not recruiting

  Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

  NCT04768062· Phase 3· NS Pharma, Inc.· Source

• Recruiting

  Randomized Study in Children and Adolescents With Migraine: Acute Treatment

  NCT04649242· Phase 3· Pfizer· Source

• Recruiting

  Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

  NCT05745532· Early phase 1· Shenzhen Hemogen· Source

• Recruiting

  A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

  NCT04462770· Phase 3· Epygenix· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers6 recruiting
• Acute lymphoblastic leukaemia5 recruiting
• Epilepsy3 recruiting
• Thalassaemia3 recruiting
• Lupus (SLE)2 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Autism1 recruiting
• Cytomegalovirus infection1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Haemophilia1 recruiting
• Migraine1 recruiting
• Neuroblastoma1 recruiting
• Rheumatoid arthritis1 recruiting
• Sjögren's disease1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Turner syndrome1 recruiting

Closed trials

• Completed

  A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65

  NCT07060885· Phase 3· ALK-Abelló A/S· Source

• Completed

  Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis

  NCT06631170· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Completed

  A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

  NCT06280716· Phase 3· Eli Lilly and Company· Source

• Terminated

  A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

  NCT05163314· Phase 3· Takeda· Source

• Completed

  A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

  NCT04938427· Phase 3· Takeda· Source

• Completed

  A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

  NCT04940624· Phase 3· Takeda· Source

• Terminated

  A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia

  NCT04925206· Phase 1· EdiGene (GuangZhou) Inc.· Source

• Terminated

  A Study of Soticlestat in Adults and Children With Rare Epilepsies

  NCT03635073· Phase 2· Takeda· Source

• Completed

  ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)

  NCT02078427· Baxalta now part of Shire· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Acute lymphoblastic leukaemia13 works · 5 trials
• Thalassaemia9 works · 5 trials